Lantheus launches Definity in India
Lantheus Medical Imaging has launched its ultrasound contrast imaging agent, Definity vial for (perflutren lipid microsphere) injectable suspension, in India.

The North Billerica, Mass.-based company has signed a multi-year agreement with Mumbai, India-based J.B. Chemicals & Pharmaceuticals for distribution and marketing of Definity in the Indian marketplace.

Definity is an ultrasound contrast imaging agent that is indicated in India for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and for the delineation of the left ventricular endocardial border, as well as for use in patients in contrast-enhanced diagnostic ultrasound imaging to improve characterization of focal lesions of the liver and kidney, Lantheus said.